Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNA-seq of two triple knockout SCLC mouse models for subtyping

ABSTRACT: scRNA-seq of two triple knockout SCLC mouse models for subtyping

PROVIDER: PRJNA566440 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10149773.fastq.gz	Fastqsanger.gz
	SRR10149774.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

scRNA-seq of triple knockout SCLC mouse models for subtyping

Project description:scRNA-seq of triple knockout SCLC mouse models for subtyping

| PRJNA872011 | ENA

scRNA-seq of two triple knockout SCLC mouse models for subtyping

Project description:Adopting a systems approach, we devise a general workflow to define actionable subtypes in human cancers. Applied to small cell lung cancer (SCLC), the workflow identifies four subtypes based on global gene expression patterns and ontologies. Three correspond to known subtypes, while the fourth is a previously undescribed neuroendocrine variant (NEv2). Tumor deconvolution with subtype gene signatures shows that all of the subtypes are detectable in varying proportions in human and mouse tumors. To understand how multiple stable subtypes can arise within a tumor, we infer a network of transcription factors and develop BooleaBayes, a minimally-constrained Boolean rule-fitting approach. In silico perturbations of the network identify master regulators and destabilizers of its attractors. Specific to NEv2, BooleaBayes predicts ELF3 and NR0B1 as master regulators of the subtype, and TCF3 as a master destabilizer. Since the four subtypes exhibit differential drug sensitivity, with NEv2 consistently least sensitive, these findings may lead to actionable therapeutic strategies that consider SCLC intratumoral heterogeneity. Our systems-level approach should generalize to other cancer types.

2019-09-20 | GSE137749 | GEO

scRNA-seq of triple knockout SCLC mouse models for subtyping

Project description:Small cell lung cancer (SCLC) tumors comprise heterogeneous mixtures of cell states, categorized into neuroendocrine (NE) and non-neuroendocrine (non-NE) transcriptional subtypes. NE to non-NE state transitions, fueled by plasticity, likely underlie adaptability to treatment and dismal survival rates. Here, we apply an archetypal analysis to model plasticity by recasting SCLC phenotypic heterogeneity through multi-task evolutionary theory. Cell line and tumor transcriptomics data fit well in a five-dimensional convex polytope whose vertices optimize tasks reminiscent of pulmonary NE cells, the SCLC normal counterparts. These tasks, supported by knowledge and experimental data, include proliferation, slithering, metabolism, secretion, and injury repair, reflecting cancer hallmarks. SCLC subtypes, either at the population or single-cell level, can be positioned in archetypal space by bulk or single-cell transcriptomics, respectively, and characterized as task specialists or multi-task generalists by the distance from archetype vertex signatures. In the archetype space, modeling single-cell plasticity as a Markovian process along an underlying state manifold indicates that task trade-offs, in response to microenvironmental perturbations or treatment, may drive cell plasticity. Stifling phenotypic transitions and plasticity may provide new targets for much-needed translational advances in SCLC.

2022-08-22 | GSE211751 | GEO

RNAseq analysis of SCLC PDX models

Project description:We investigated the gene expression changes in a library of small cell lung carcinoma (SCLC) patient-derived xenograft (PDX) models.

2022-02-07 | E-MTAB-11230 | biostudies-arrayexpress

RNAseq analysis of SCLC PDX models

Project description:RNAseq analysis of SCLC PDX models

| PRJEB50684 | ENA

RNA-seq of SCLC PDX models treated with EP

Project description:We report the correlation of transcript abundance with response to EP in 19 PDX models of SCLC

2018-03-06 | GSE110853 | GEO

Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping

Project description:Triple-negative breast cancer (TNBC) is considered the most aggressive type of breast cancer with limited options for therapy. TNBC is a heterogeneous disease and tumours has been classified into TNBC subtypes using gene expression profiling to distinguish basal-like1 (BL1), basal-like2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal/stem-like (MSL), luminal androgen receptor (LAR) and one non-classifiable group (called unstable, UNS). The aim of this study was to verify the clinical relevance of molecular subtyping of TNBCs by expression analysis to improve the individual indication of systemic therapy.

2021-07-31 | GSE167213 | GEO

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [scRNA-seq]

Project description:We thoroughly analyzed the molecular subtyping of Triple-Negative Breast Cancer and its different manifestations, and located T cells and Tumor cells related to the survival of breast cancer through single cell sequencing and space transcriptome according to our score, and finally investigated their relationship with the therapeutic efficacy, providing a scientific basis for the treatment of triple negative breast cancer.

2024-05-17 | GSE252175 | GEO

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [Spatial Transcriptome seq]

2024-05-17 | GSE252176 | GEO

Gene-expression molecular subtyping of triple-negative breast cancer tumors

Project description:Gene-expression molecular subtyping of triple-negative breast cancer tumors

| PRJNA400182 | ENA